[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-565774-105":53,"doc-detail-565774-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","numelvi-product-summary-veterinary-medicinal-product-characteristics","Numelvi - Product Summary - Veterinary Medicinal Product Characteristics","","Product characteristics summary for Numelvi 7.2 mg tablets for dogs, listing qualitative and quantitative composition, tablet description, and physicochemical presentation. Provides clinical information including target species, indications for allergic dermatitis–associated pruritus and atopic dermatitis manifestations, contraindications, and special precautions. Covers adverse events and reporting, use restrictions during pregnancy, lactation, and fertility, interaction information with other veterinary medicinal products and vaccines, and oral administration with a weight-based daily dosing table.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":36,"@type":70,"position":76},"https://docshare.wps.com/template/forms/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/numelvi-product-summary-veterinary-medicinal-product-characteristics/565774/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/numelvi-product-summary-veterinary-medicinal-product-characteristics/565774.png","ImageObject",442,249,{"name":88,"@type":89},"anakgang17","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-15","2026-10-13",true,{"@type":98,"interactionType":99,"userInteractionCount":9},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What conditions does Numelvi 7.2 mg tablets for dogs treat?","Question",{"text":108,"@type":109},"Numelvi treats pruritus associated with allergic dermatitis in dogs and clinical manifestations associated with atopic dermatitis in dogs, including pruritus.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"Who should not receive Numelvi?",{"text":113,"@type":109},"Do not use it in cases of hypersensitivity to the active substance or any excipients.",{"name":115,"@type":106,"acceptedAnswer":116},"How is Numelvi administered and what dosing guidance is provided?",{"text":117,"@type":109},"Use is oral once daily at the recommended dose range of 0.8 to 1.2 mg atinvicitinib per kg bodyweight around feeding time, with a weight-band dosing table. The tablets are breakable along the score line.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},565774,1792107094,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":35,"category_name":36,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":9,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":135,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":73},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Issued: February 2026  \nAN: 03856/2024  \nSUMMARY OF PRODUCT CHARACTERISTICS  \n1. NAME OF THE VETERINARY MEDICINAL PRODUCT  \nNumelvi 7.2 mg tablets for dogs  \n2. QUALITATIVE AND QUANTITATIVE COMPOSITION  \nEach tablet contains:  \nActive substance:  \nAtinvicitinib 7.2 mg  \nExcipients:  \n\n| Qualitative composition of excipients and other constituents |\n| --- |\n| Cellulose, microcrystalline |\n| Lactose monohydrate |\n| Sodium starch glycolate (type A) |\n| Tocofersolan |\n| Hydroxypropylcellulose |\n| Silica, colloidal anhydrous |\n| Magnesium stearate |\n\nWhite to off-white, oblong shaped tablets with one score-line on each side and marked with \"M\" on each half of the top side.  \nThe tablets can be divided into two equal halves.  \n3. CLINICAL INFORMATION  \n3.1 Target species  \nDogs.  \n3.2 Indications for use for each target species  \nFor the treatment of pruritus associated with allergic dermatitis in dogs.  \nFor the treatment of the clinical manifestations associated with atopic dermatitis in dogs, including pruritus.  \n3.3 Contraindications  \nDo not use in cases of hypersensitivity to the active substance or to any of the excipients.  \n3.4 Special warnings  \nNone.  \nIssued: February 2026  \nAN: 03856/2024  \n3.5 Special precautions for use  \nSpecial precautions for safe use in the target species:  \nSafety of this veterinary medicinal product has not been investigated in dogs younger than 6 months of age. Use of the veterinary medicinal product in younger animals should be based on a benefit-risk assessment by the responsible veterinarian. Complicating factors such as bacterial, fungal or parasitic infections (e.g. , fleas, Demodex mites), in addition to any underlying causes of allergic and atopic dermatitis (e.g. , flea allergy, contact allergy, food allergy) should be investigated and treated.  \nUse of the veterinary medicinal product has not been evaluated in combination with systemic immunosuppressive agents such as glucocorticoids, cyclosporine or other immunosuppressive agents. Furthermore, the safety of the veterinary medicinal product has not been investigated in dogs with evidence of immunosuppression (for example, uncontrolled primary hypothyroidism, rickettsial disease) or dogs with evidence of progressive malignant neoplasia. Use in such cases should be based on a benefit-risk assessment by the responsible veterinarian.  \nSpecial precautions to be taken by the person administering the veterinary medicinal product to animals:  \nWash hands thoroughly with soap and water immediately after use of the veterinary medicinal product.  \nSpecial precautions for the protection of the environment: Not applicable.  \n3.6 Adverse events  \nDogs:  \n\n| Common\u003Cbr>(1 to 10 animals / 100 animals treated): | Emesis, diarrhoea. Lethargy, anorexia. |\n| --- | --- |\n\nReporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.  \n3.7 Use during pregnancy, lactation or lay  \nThe safety of the veterinary medicinal product has not been established during pregnancy and lactation or in breeding dogs.  \nPregnancy and lactation:  \nThe use of the veterinary medicinal product during pregnancy and lactation is not recommended. Laboratory studies in rats and rabbits have shown effects on prenatal development inherent to the class of JAK inhibitors.  \nIssued: February 2026  \nAN: 03856/2024  \nFertility:  \nThe use of the veterinary medicinal product is not recommended in breeding animals. Laboratory studies in male rats showed an effect on sperm counts and sperm motility.  \n3.8 Interaction with other medicinal products and other forms of interaction  \nNo drug interactions were observed in field studies where the veterinary medicinal product was administered concomitantly with other veterinar","cbCaipLW4uLHQldN","https://ap.wps.com/l/cbCaipLW4uLHQldN","pdf",93042,6,"English","# SUMMARY OF PRODUCT CHARACTERISTICS\n## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT\n## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION\n## 3. CLINICAL INFORMATION\n## 3.1 Target species\n## 3.2 Indications for use\n## 3.3 Contraindications\n## 3.4 Special warnings\n## 3.5 Special precautions for use\n## 3.6 Adverse events\n## 3.7 Use during pregnancy, lactation or lay\n## 3.8 Interaction with other medicinal products\n## 3.9 Administration routes and dosage","[{\"question\":\"What conditions does Numelvi 7.2 mg tablets for dogs treat?\",\"answer\":\"Numelvi treats pruritus associated with allergic dermatitis in dogs and clinical manifestations associated with atopic dermatitis in dogs, including pruritus.\"},{\"question\":\"Who should not receive Numelvi?\",\"answer\":\"Do not use it in cases of hypersensitivity to the active substance or any excipients.\"},{\"question\":\"How is Numelvi administered and what dosing guidance is provided?\",\"answer\":\"Use is oral once daily at the recommended dose range of 0.8 to 1.2 mg atinvicitinib per kg bodyweight around feeding time, with a weight-band dosing table. The tablets are breakable along the score line.\"}]","Numelvi - Product Summary - Veterinary Medicinal Product Characteristics | PDF",1791857965]